FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to recombinant production of monoclonal antibodies to a glucagon receptor (hereinafter – GCGR); it can be used in medicine for reduction in glucose concentration in blood. Monoclonal antibodies to GCGR are proposed, containing certain combinations of a heavy chain variable region and a light chain variable region.
EFFECT: invention provides obtainment of antibodies specifically binding to GCGR and bispecific proteins based on them, also including GLP-1 peptide, effective in the treatment of diabetes.
24 cl, 5 dwg, 22 tbl, 9 ex
             
         
            
              
                | Title | Year | Author | Number | 
							
              
                | CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 | 
										Fu, YayuanMa, SyaoliGe, KhuTao, Vejkan | RU2819228C2 | 
							
              
                | ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 | 
										Yan, YanGe, KhuTao, Vejkan | RU2822550C2 | 
							
              
                | CONJUGATE OF ANTI-CEA ANTIBODY AND EXCATECAN ANALOGUE AND PHARMACEUTICAL USE THEREOF | 2020 | 
										Ying HuaMao LangyongWang Sijia | RU2833323C1 | 
							
              
                | PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 | 
										Tian, ChenminLi, HaoLiu, Xun | RU2782792C2 | 
							
              
                | ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 | 
										Ying HuaZhang LingYang XiaoyingGe HuTao Weikang | RU2802272C2 | 
							
              
                | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 | 
										U, TintinLi, KhaoLyu, SyunTao, Vejkan | RU2824390C2 | 
							
              
                | CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF | 2020 | 
										Yang YangXu JianyanTao Weikang | RU2826119C1 | 
							
              
                | ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 | 
										Gu XiaolingYe XinGe HuTao Weikang | RU2807484C2 | 
							
              
                | PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 | 
										Tyan, ChenminLi, KhaoLyu, Syun | RU2791683C2 | 
							
              
                | FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 | 
										Gu, TszinminLo, SyaoTao, Vejkan | RU2776204C1 |